Haemonetics Corporation Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Devices |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NYSE |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Haemonetics Corporation (HAE) holds an ST Score of 61.5 out of 100 (B), with its strongest factor being Profitability (A) and its weakest Valuation (D+). Analysts rate HAE Buy across 21 ratings with a $108.60 average price target (+0.0% vs the current $108.42).
- Strongest
- ProfitabilityA
- Weakest
- ValuationD+
All factor grades
- ProfitabilityA
- MomentumA
- ForecastB
- Financial StrengthC
- GrowthC
- ValuationD+
- Piotroski8/9
Contact
HAE stock: frequently asked questions
What is HAE's ST Score?
Haemonetics Corporation (HAE) has an ST Score of 61.5 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is HAE a buy, sell, or hold?
Wall Street's consensus rating on HAE is Buy based on 21 analyst ratings. Our own ST Score grades it B (61.5/100). This is data, not investment advice — always do your own research.
What is HAE's valuation grade?
Haemonetics Corporation (HAE) earns a valuation grade of D+, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is HAE's growth grade?
Haemonetics Corporation (HAE) earns a growth grade of C, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is HAE's profitability grade?
Haemonetics Corporation (HAE) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is HAE's financial strength grade?
Haemonetics Corporation (HAE) earns a financial strength grade of C, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for HAE?
The average analyst price target for Haemonetics Corporation (HAE) is $108.60 from 21 analysts, which is +0.0% versus the recent price of $108.42.
What is HAE's Piotroski score?
Haemonetics Corporation (HAE) has a Piotroski F-Score of 8 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.